• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 4 filed by Director Torstad Elisabeth

    5/6/25 6:00:41 PM ET
    $ULS
    Precision Instruments
    Health Care
    Get the next $ULS alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Torstad Elisabeth

    (Last) (First) (Middle)
    C/O UL SOLUTIONS INC.
    333 PFINGSTEN ROAD

    (Street)
    NORTHBROOK IL 60062

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    UL Solutions Inc. [ ULS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    04/18/2024
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Deferred Restricted Stock Unit (1) 05/01/2024 A 4,878 (2) (2) Class A Common Stock 4,878 $0 4,878 D
    Explanation of Responses:
    1. Each deferred restricted stock unit represents the contingent right to receive one share of the Issuer's Class A Common Stock.
    2. The deferred restricted stock units will vest on the earlier of the one-year anniversary of the grant date or the date of the annual meeting following the grant date and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the reporting person pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), or (ii) as otherwise provided by the Plan.
    Remarks:
    The deferred restricted stock unit grant was inadvertently reported early on April 18, 2024 and was subsequently reported on a second Form 4 filed on May 23, 2024. This amendment corrects the title of the security, the number of derivative securities acquired, the number of derivative securities beneficially owned following the reported transaction and the vesting thereof.
    /s/ Ryan Robinson, Attorney-in-Fact 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ULS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ULS

    DatePrice TargetRatingAnalyst
    10/7/2024$60.00Buy
    Citigroup
    7/12/2024$41.00 → $46.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ULS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UL Solutions Inc. Reports Strong First Quarter 2025 Results

      First Quarter 2025 (Comparisons to First Quarter 2024 unless otherwise noted)1 Strong revenue growth of 5.2% to $705 million, including 7.6% organic growth Net income of $71 million increased 18.3%, Net income margin of 10.1%, expanded 110 basis points Diluted earnings per share of $0.33 increased 17.9%, Adjusted Diluted Earnings Per Share of $0.37 increased 32.1% Adjusted EBITDA of $161 million increased 22.9%, Adjusted EBITDA margin of 22.8% expanded 320 basis points UL Solutions Inc. (NYSE:ULS), a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the firs

      5/6/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Earns Platinum Medal from EcoVadis for Sustainability Performance

      Achieving the top EcoVadis rating reflects the safety science company's commitment to corporate sustainability UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that it has achieved a Platinum Medal from EcoVadis, a leader in business sustainability assessments, placing it in the top 1% of companies assessed by EcoVadis globally in the past 12 months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421295124/en/ UL Solutions improved its rating from Silver – bypassing Gold – to reach EcoVadis' top Platinum rating this year. More than 150,000 companies have been rated by EcoVadis. "We are

      4/22/25 12:25:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. Sets Date for First Quarter 2025 Results

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it will release financial results for the first quarter 2025 before the market opens on Tuesday, May 6. Management will host a webcast and conference call that same day at 8:30 a.m. EDT (7:30 a.m. CDT) to review results. Webcast and Conference Call The conference call will be broadcast live over the Internet. Additionally, a slide presentation will accompany the conference call. To listen to the call and view the slides, please visit the Investors section of UL Solutions' website at www.ul.com. For those who are unable to listen to the live broadcast, an audio replay of the conference call will be ava

      4/22/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by UL Solutions Inc.

      SC 13G/A - UL Solutions Inc. (0001901440) (Subject)

      11/13/24 12:26:41 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UL Solutions Inc.

      SC 13G/A - UL Solutions Inc. (0001901440) (Subject)

      11/12/24 5:49:12 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by UL Solutions Inc.

      SC 13G - UL Solutions Inc. (0001901440) (Subject)

      11/12/24 10:34:15 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CCO Uggetti Alberto sold $137,270 worth of shares (1,961 units at $70.00), decreasing direct ownership by 17% to 9,285 units (SEC Form 4)

      4 - UL Solutions Inc. (0001901440) (Issuer)

      5/9/25 6:45:06 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Officer Schjotz Gitte sold $472,080 worth of shares (7,000 units at $67.44), decreasing direct ownership by 13% to 46,889 units (SEC Form 4)

      4 - UL Solutions Inc. (0001901440) (Issuer)

      5/9/25 4:30:10 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Director Lambert Lisa Marie converted options into 4,927 shares, increasing direct ownership by 552% to 5,819 units (SEC Form 4)

      4 - UL Solutions Inc. (0001901440) (Issuer)

      5/6/25 6:00:50 PM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by UL Solutions Inc.

      SCHEDULE 13G - UL Solutions Inc. (0001901440) (Subject)

      5/6/25 5:16:10 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form 10-Q filed by UL Solutions Inc.

      10-Q - UL Solutions Inc. (0001901440) (Filer)

      5/6/25 4:16:26 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - UL Solutions Inc. (0001901440) (Filer)

      5/6/25 7:01:34 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Financials

    Live finance-specific insights

    See more
    • UL Solutions Inc. Reports Strong First Quarter 2025 Results

      First Quarter 2025 (Comparisons to First Quarter 2024 unless otherwise noted)1 Strong revenue growth of 5.2% to $705 million, including 7.6% organic growth Net income of $71 million increased 18.3%, Net income margin of 10.1%, expanded 110 basis points Diluted earnings per share of $0.33 increased 17.9%, Adjusted Diluted Earnings Per Share of $0.37 increased 32.1% Adjusted EBITDA of $161 million increased 22.9%, Adjusted EBITDA margin of 22.8% expanded 320 basis points UL Solutions Inc. (NYSE:ULS), a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the firs

      5/6/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. Sets Date for First Quarter 2025 Results

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it will release financial results for the first quarter 2025 before the market opens on Tuesday, May 6. Management will host a webcast and conference call that same day at 8:30 a.m. EDT (7:30 a.m. CDT) to review results. Webcast and Conference Call The conference call will be broadcast live over the Internet. Additionally, a slide presentation will accompany the conference call. To listen to the call and view the slides, please visit the Investors section of UL Solutions' website at www.ul.com. For those who are unable to listen to the live broadcast, an audio replay of the conference call will be ava

      4/22/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Announces Increased Quarterly Dividend

      UL Solutions Inc. (NYSE:ULS), a global safety science leader, today announced that its board of directors has declared a quarterly dividend of $0.13 per share, an increase of $0.005 per share, bringing the annual dividend rate to $0.52 per share, up 4% from the previous annual rate. The dividend will be paid on March 10, 2025, to shareholders of record as of the close of business on Feb. 28, 2025. "UL Solutions is pleased to increase our quarterly dividend and provide this additional return to shareholders," said Jennifer Scanlon, president and CEO. About UL Solutions A global leader in applied safety science, UL Solutions Inc. transforms safety, security and sustainability challenges

      2/12/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup resumed coverage on UL Solutions Inc. with a new price target

      Citigroup resumed coverage of UL Solutions Inc. with a rating of Buy and set a new price target of $60.00

      10/7/24 8:45:25 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded UL Solutions Inc. from Outperform to Neutral and set a new price target of $46.00 from $41.00 previously

      7/12/24 7:43:51 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Leadership Updates

    Live Leadership Updates

    See more
    • UL Solutions Inc. Names New Chief Legal Officer

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it appointed Scott D'Angelo as executive vice president and chief legal officer, effective April 21, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311928632/en/UL Solutions names Scott D'Angelo as executive vice president and chief legal officer (Photo: Business Wire) D'Angelo's appointment fills a vacant role and he joins the company's executive leadership team, reporting to President and CEO Jennifer Scanlon. D'Angelo will oversee the legal, brand integrity, ethics and compliance functions. He most recently served as vice presiden

      3/11/25 9:15:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Names Chief Business Operations and Innovation Officer

      Alex Dadakis to join UL Solutions leadership team in newly created role UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it appointed Alex Dadakis as Executive Vice President, Chief Business Operations and Innovation Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205299962/en/UL Solutions announced the appointment of Alex Dadakis as Executive Vice President, Chief Business Operations and Innovation Officer, effective Jan. 27, 2025. (Photo: Business Wire) Dadakis, who most recently served as Senior Vice President, Global Head of Strategy and Corporate Development at Germany-ba

      12/5/24 4:15:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Acquires Germany-Based Battery Testing and Simulation Company BatterieIngenieure

      Deal deepens UL Solutions' global expertise in battery performance testing and expands our global EV battery testing footprint. UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced our acquisition of BatterieIngenieure GmbH, a battery testing company based in Aachen, Germany, with expertise in specialized performance testing of cell, small modules and battery systems used in electric vehicles and other applications. The acquisition augments UL Solutions' global battery testing footprint with a laboratory in Europe. BatterieIngenieure provides comprehensive testing, simulation and failure analysis of battery technologies, with distinctive expertise in

      5/22/24 8:30:00 AM ET
      $ULS
      Precision Instruments
      Health Care